Novo Nordisk to test next-gen obesity drug CagriSema in children

Core Insights - Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight children and adolescents [1] Company Summary - The company is known for its existing obesity treatment, Wegovy, and is expanding its research into new demographics [1] Industry Summary - The obesity treatment market is seeing increased interest in pediatric applications, reflecting a growing recognition of childhood obesity as a significant health issue [1]